A meta-analysis published in the New England Journal of Medicine of 511 studies found peer-reviewed evidence supports the safety and effectiveness of vaccines for COVID-19, respiratory syncytial virus (RSV), and influenza during the 2025–2026 season. The COVID-19 vaccines for the XBB.1.5 variant had a pooled vaccine effectiveness against hospitalization of 46-50% among adults and 37% among adults with weakened immune systems, according to the analysis. For RSV, vaccines had pooled estimates of 68% for maternal …
Read More





